48 related articles for article (PubMed ID: 15833886)
1. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis.
Medina D; Kittrell FS; Hill J; Shepard A; Thordarson G; Brown P
Cancer Res; 2005 Apr; 65(8):3493-6. PubMed ID: 15833886
[TBL] [Abstract][Full Text] [Related]
2. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models.
Rajkumar L; Kittrell FS; Guzman RC; Brown PH; Nandi S; Medina D
Breast Cancer Res; 2007; 9(1):R12. PubMed ID: 17257424
[TBL] [Abstract][Full Text] [Related]
3. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis.
Sivaraman L; Conneely OM; Medina D; O'Malley BW
Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12379-84. PubMed ID: 11606748
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen Modulates the Immune Landscape of the Tumour Microenvironment: The Paired Siglec-5/14 Checkpoint in Anti-Tumour Immunity in an In Vitro Model of Breast Cancer.
Wielgat P; Rogowski K; Czarnomysy R; Wawrusiewicz-Kurylonek N; Narejko K; Bielawski K; Car H
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982588
[TBL] [Abstract][Full Text] [Related]
5. Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.
Cornelissen LM; Henneman L; Drenth AP; Schut E; de Bruijn R; Klarenbeek S; Zwart W; Jonkers J
J Mammary Gland Biol Neoplasia; 2019 Dec; 24(4):305-321. PubMed ID: 31729597
[TBL] [Abstract][Full Text] [Related]
6. Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.
Palaniappan M; Edwards D; Creighton CJ; Medina D; Conneely OM
PLoS One; 2018; 13(3):e0194913. PubMed ID: 29590203
[TBL] [Abstract][Full Text] [Related]
7. Oestrogen receptor negativity in breast cancer: a cause or consequence?
Gajulapalli VNR; Malisetty VL; Chitta SK; Manavathi B
Biosci Rep; 2016 Dec; 36(6):. PubMed ID: 27884978
[TBL] [Abstract][Full Text] [Related]
8. Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo.
O'Leary KA; Jallow F; Rugowski DE; Sullivan R; Sinkevicius KW; Greene GL; Schuler LA
Endocrinology; 2013 Dec; 154(12):4483-92. PubMed ID: 24064365
[TBL] [Abstract][Full Text] [Related]
9. Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.
O'Leary KA; Rugowski DE; Sullivan R; Schuler LA
Oncogene; 2014 Jun; 33(23):3075-82. PubMed ID: 23873024
[TBL] [Abstract][Full Text] [Related]
10. Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.
Tarulli GA; De Silva D; Ho V; Kunasegaran K; Ghosh K; Tan BC; Bulavin DV; Pietersen AM
Breast Cancer Res; 2013 Jan; 15(1):R10. PubMed ID: 23369183
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy-induced changes in breast cancer risk.
Russo IH; Russo J
J Mammary Gland Biol Neoplasia; 2011 Sep; 16(3):221-33. PubMed ID: 21805333
[TBL] [Abstract][Full Text] [Related]
12. The effects of Tamoxifen and fish oil on mammary carcinogenesis in polyoma middle T transgenic mice.
Manni A; Xu H; Washington S; Aliaga C; Das A; Cooper T; Richie JP; Prokopczyk B; Calcagnotto A; Trushin N; Van den Heuvel JP; Hamilton C; Demers LM; Liao J; Verderame MF; El-Bayoumy K
Horm Cancer; 2011 Aug; 2(4):249-59. PubMed ID: 21769696
[TBL] [Abstract][Full Text] [Related]
13. Choosing a mouse model: experimental biology in context--the utility and limitations of mouse models of breast cancer.
Borowsky AD
Cold Spring Harb Perspect Biol; 2011 Sep; 3(9):a009670. PubMed ID: 21646376
[TBL] [Abstract][Full Text] [Related]
14. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.
Herschkowitz JI; Zhao W; Zhang M; Usary J; Murrow G; Edwards D; Knezevic J; Greene SB; Darr D; Troester MA; Hilsenbeck SG; Medina D; Perou CM; Rosen JM
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2778-83. PubMed ID: 21633010
[TBL] [Abstract][Full Text] [Related]
15. Of mice and women: A short history of mouse mammary cancer research with an emphasis on the paradigms inspired by the transplantation method.
Medina D
Cold Spring Harb Perspect Biol; 2010 Oct; 2(10):a004523. PubMed ID: 20630995
[TBL] [Abstract][Full Text] [Related]
16. Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors.
Rose-Hellekant TA; Skildum AJ; Zhdankin O; Greene AL; Regal RR; Kundel KD; Kundel DW
Cancer Prev Res (Phila); 2009 May; 2(5):496-502. PubMed ID: 19401525
[TBL] [Abstract][Full Text] [Related]
17. Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.
Medina D; Kittrell F; Hill J; Zhang Y; Hilsenbeck SG; Bissonette R; Brown PH
Cancer Prev Res (Phila); 2009 Feb; 2(2):168-74. PubMed ID: 19174577
[TBL] [Abstract][Full Text] [Related]
18. The relevance of mouse models to understanding the development and progression of human breast cancer.
Allred DC; Medina D
J Mammary Gland Biol Neoplasia; 2008 Sep; 13(3):279-88. PubMed ID: 18704660
[TBL] [Abstract][Full Text] [Related]
19. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.
Zhang M; Behbod F; Atkinson RL; Landis MD; Kittrell F; Edwards D; Medina D; Tsimelzon A; Hilsenbeck S; Green JE; Michalowska AM; Rosen JM
Cancer Res; 2008 Jun; 68(12):4674-82. PubMed ID: 18559513
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-alpha expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice.
Feng Y; Manka D; Wagner KU; Khan SA
Proc Natl Acad Sci U S A; 2007 Sep; 104(37):14718-23. PubMed ID: 17785410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
